Development of a Fluorescence Polarization Based High-Throughput Assay to Identify Casitas B-Lineage Lymphoma RING Domain Regulators

Xingliang Xie1, Lin Sun2, Ziyan Yuan Pessetto3, Yan Zhao1, Zhihe Zang1, Ling Zhong1, Min Wu1, Qing Su1, Xiurong Gao1, Wang Zan1, Yiyi Sun1*

1 Department of Pharmacy, Chengdu Medical College, Chengdu, Sichuan Province, China, 2 West China Hospital, Sichuan University, Chengdu, Sichuan Province, China, 3 Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States of America

Abstract

The E3 ubiquitin protein ligase Casitas B-lineage Lymphoma (Cbl) proteins and their binding partners play an important role in regulating signal transduction pathways. It is important to utilize regulators to study the protein-protein interactions (PPIs) between these proteins. However, finding specific small-molecule regulators of PPIs remains a significant challenge due to the fact that the interfaces involved in PPIs are not well suited for effective small molecule binding. We report the development of a competitive, homogeneous, high-throughput fluorescence polarization (FP) assay to identify small molecule regulators of Cbl (RING) domain. The FP assay was used to measure binding affinities and inhibition constants of UbCH7 peptides and small molecule regulators of Cbl (RING) domains, respectively. In order to rule out promiscuous, aggregation-based inhibition, two assay conditions were developed and compared side by side. Under optimized conditions, we screened a 10,000 natural compound library in detergent-free and detergent-present (0.01% Triton X-100) systems. The results indicate that the detergent-present system is more suitable for high-throughput screens. Three potential compounds, methylprotodioscin, leonuride and catalpol, have been identified that bind to Cbl (RING) domain and interfere with the Cbl (RING)-UbCH7 protein-protein interaction.

Introduction

The casitas B-lineage Lymphoma (Cbl) proteins have created much interest in recent years. So far seven members of Cbl-family proteins have been characterized including three mammalian isoforms (c-Cbl, Cbl-b, Cbl-c/Cbl-3), two isoforms in Drosophila melanogaster (Fly Cbl, short and long), Caenorhabditis elegans (SLI-1), and chick Cbl [1,2]. In addition, there are four known oncogenic Cbl proteins including v-Cbl, 70Z-Cbl, ΔY368-Cbl and ΔY371-Cbl [1] (Fig. S1). The oncogenic protein v-Cbl, the first member of the Cbl-family proteins, was cloned from the Cas NS-1 retrovirus in 1989 [3]. Later, it was subsequently discovered that v-Cbl is a truncated form of a larger cellular homologue known as c-Cbl [4]. c-Cbl is a ubiquitously expressed, primarily cytosolic protein which has 906 and 913 amino acids in humans and mice, respectively [5]. The full length of c-Cbl consists of an N-terminal tyrosine-kinase-binding (TKB) domain, a RING Finger motif, a proline-rich region and a C-terminal ubiquitin-associated (UBA) domain that overlaps with a LEUCINE ZIPPER (LZ) motif [1].

By virtue of its E3 ubiquitin ligase activity, c-Cbl is widely known as a negative regulator of growth factor action. Signaling proteins known to be targeted for ubiquitination by c-Cbl proteins include EGF receptor, PDGF receptor, Macrophage Colony-Stimulating Factor (M-CSF) receptor, Neu receptor, Epidermal Growth Factor-2 (ErbB-2) receptor, c-Src, c-Chi, and T-cell and B-cell antigen receptor [6,7]. Inhibition of this process results in enhanced signal transduction [1]. In addition to the E3 ubiquitin ligase activity, c-Cbl has been reported to act as an adaptor protein in a range of intracellular signaling cascades [1,8].

The Cbl family of ubiquitin ligases, along with a set of phosphotyrosine-binding adaptors, integrates receptor endocytosis into the densely wired networks of signal transduction, which plays a vital role in health and disease. However, the mechanism is not well understood due to limited techniques to dissect Cbl protein functions. Here we designed a competitive, homogeneous, high-throughput FP assay to identify small molecule regulators that binds to Cbl (RING) domain.

Materials and Methods

Peptides and Proteins

Peptides (Table 1) were purchased from Pharmarie (Chengu, Shihua, China) with a purity ≥98%. The peptide concentrations were determined by amino acid analysis at the protein core facility.
were calculated. The concentrations of fluorescein-labeled peptide and protein concentration, and the dissociation constant (Kd) and the change in mP (ΔmP) were obtained from the resulting sigmoidal curve. The concentrations of fluorescein-labeled peptide and proteins were optimized.

**Compound Library**

The natural product library contains 10,000 natural products with a minimum of 98% purity confirmed by NMR and HPLC (Pharmamic, Chengdu, Sichuan, China). Compounds are selected according to Pharmacopoeia of the People’s Republic of China. All compounds are approved by China Food and Drug Administration as Chinese Traditional Medicine. Compounds were present at 10 mmol/L in DMSO. Compounds were seeded from A2 to H11 in 96-well plates.

**Reagents**

All the chemicals are purchased from Kepeng Ltd (Beijing, China) except specific indication.

**FP Assay Development**

Assays were carried out in detergent-free buffer system (PBS, pH = 7.4) or detergent-present buffer system (0.01% Triton X-100 in PBS, pH = 7.4). All FP measurements were made on 384-well, low-volume, black, v-bottom polystyrene microplates (Corning, Shanghai, China) using the ZS-2 plate reader. The binding affinities of fluorescein-labeled peptides/regulators binding to c-Cbl (RING) protein were verified by titrating an increasing concentration of protein into a constant concentration of labeled peptides. The polarization values were measured at an excitation wavelength of 485 nm and an emission wavelength of 538 nm. The total fluorescence (TF) values were also measured. The change in polarization was graphed as a function of the log of the protein concentration, and the dissociation constant (Kd) and the change in mP (ΔmP) were obtained from the resulting sigmoidal curve. The concentrations of fluorescein-labeled peptide and proteins were optimized.

**FP Assay Stability Assessment**

Unlabeled short peptide was titrated against the FITC-labeled peptide (100 mmol/L) and protein (3 μmol/L) mixture. Plates were incubated at room temperature for up to 3 hours or 30 min at different temperatures. FP values were taken and IC50 values, concentrations giving 50% inhibition of protein-protein interaction with respect to control, and dissociation constant (Kd) values were calculated.

**DMSO Tolerance Assay**

Increasing concentrations of DMSO at 1–20% of the assay volume (20 μL) were added to the FITC-labeled peptide and protein mixture. FP and TF measurements were taken at room temperature (25 °C) after 30 min incubation.

**FP Based Screen**

Master mixtures containing fluorescein-labeled probe and Cbl (RING) protein Cbl (RING) protein, 3 μmol/L and probe 1 at 100 mmol/L were prepared and loaded to plates. The library compounds (10 μmol/L – 0.078 μmol/L, half dilutions) were prepared separately and transferred into the assay plates. The first and last columns of each plate were used as positive and negative control wells. Wells containing the drug only were used as controls to detect auto-fluorescence of the compounds in the total fluorescence assay. After subtraction of the background signal, data was processed and the IC50 values were determined by non-linear least square fitting (four parameters) using SigmaPlot 11.0.

**Hits Validation**

Hits were validated using the primary screening assay conditions in triplicate.

**Statistical Analysis**

Data were reported as mean ± SD. Each experiment was performed 3–5 times, each treatment performed in duplicate or triplicate.

**Results**

**Screen Assay Development**

We hypothesized that unlabeled or fluorescein-labeled peptides (Peptide 1, Probe 1 and 2, Table 1) derived from UbCH7 structure bind to the Cbl (RING) domain and can be used to identify compounds/chemical regulators that competitively bind to the Cbl (RING) domain.

The FP assay utilizing fluorescein-labeled peptides binding to the Cbl (RING) domain was developed and optimized in a 384-well format. Two probes were designed to determine the effect of FITC on the assay. Binding experiments were performed and Kd values were calculated. Titration of c-Cbl (RING) protein with these probes causes the FP and the fluorescence anisotropy (FA) to increase 4 to 6-fold. Binding affinities to probe 1 and 2 were evaluated (Fig. 1C&D). Probe 2 binds to c-Cbl (RING) protein with a higher affinity (Kd1 = 0.14 ± 0.08 μmol/L, Fig. 1D) than probe 1 (Kd1 = 1.67 ± 0.09 μmol/L, Fig. 1C). To study competitive inhibition using the FP binding assay, the concentration ratio between the receptors and the Kd of the labeled probes should be at least 1 in order to generate IC50 curve [10]. Therefore, probe 1 was chosen for the following validation and screening assays. In addition, the receptor concentration needed for the FP assay should be ≥ Kd and should have a reasonable ΔmP. The ΔmP value was about 100 units when 3 μmol/L c-Cbl (RING) protein was titrated. Therefore, 3 μmol/L was used as the c-Cbl (RING) protein concentration for the following screen.

To determine whether probe 1 binds to the active site of c-Cbl (RING) protein and to choose a positive control, competition assays were carried out using peptide 1 (Ac-PKPPP-NH2) or mutant peptide 2 (Ac-PAKPP-NH2) (Fig. 2). We predicted that peptide 1 will be able to replace probe 1 and peptide 2, which lacks the active phenylalanine residue, will not be able to do so. The addition of peptide 1 was shown to cause the return of the FP values to the level of free probes (Fig. 2A), which indicates the ability of peptide 1 to replace probe 1. The IC50 value for probe 1 binding to c-Cbl (RING) protein in detergent-free system is 1.05 ± 0.09 μmol/L. However, the addition of mutant peptide 2 lacks the active phenylalanine residue, will not be able to do so.
does not alter the FP values, which is consistent with the prediction (Fig. 2A). To determine whether adding detergent to the assay buffer would change the dynamic stability, assays conducted in Figure 2A have been repeated under same conditions except the buffer contains 0.01% Triton X-100. The IC50 value for probe 1 binding to c-Cbl(RING) protein in the presence of detergent is 1.06 ± 0.09 μmol/L (Fig. 2B) which is comparable to the IC50 value in detergent-free system. Probe 2 does not bind to c-Cbl(RING) protein under detergent-present condition (Fig. 2B).

To optimize the FP assay properly, it was necessary to assess the stability of the assay. The conditions for the FP assay were established by testing various parameters including incubation temperature, time, TF values, ΔmP values, DMSO tolerance, and buffer components. The Kd values increased and ΔmP values decreased significantly when the plates were heated over 35°C, indicating the probe-protein system started to dissociate (Fig. 2C & D). Our data show that at room temperature (25°C) the systems are stable up to 3 h (Fig. 2E). Therefore, the incubation time was optimized to 30 min for rapid screening. The DMSO tolerance for the FP assay was also tested, and stable FP values (Fig. 2F) and TF values (data not shown) were observed at up to 15% DMSO in PBS buffer (v/v). In summary, the competitive FP binding assay conditions ideal for identifying c-Cbl (RING) domain regulator are: (1) 3 μmol/L c-Cbl (RING) protein, (2) 100 nmol/L probe 1, (3) 5% final DMSO concentration (v/v), (4) incubation for 30 min at 25°C before reading the plate, (5) with or without 0.01% Triton X-100.

Pilot Screens and Assay Performance Measurements

Pilot screens against the natural product library of 10,000 compounds described above was performed at screening concentrations of 10 μmol/L to 0.078 μmol/L (half serial dilutions) in 5% DMSO (v/v). The screens were completed in the detergent-free assay first and the detergent-present assay later. Controls present in each assay plate consisted of 5% DMSO (negative control) or peptide 1 (positive control). The assay was semi-automated and the steps are listed in Table 2. The performance of the FP assays and post-screen analysis were summarized in Table 3. Assay performance was assessed using Z' factor generated from whole DMSO plates.
Post Screen Analysis
We screened a library of 10,000 natural compounds for c-Cbl (RING) domain regulators. 3855 compounds were excluded from the post-screen validation in both detergent-free and detergent-present systems if the compounds exhibited: (1) auto fluorescence, (2) quenching of fluorescence, (3) precipitation from assay, or (4) a decrease in polarization signal while lacking a dose response. There are 422 compounds showed inhibitory activity at the concentration of 10 μmol/L. Five candidates, methylprotodioscin, leonuride, catalpol, tehmaglutin and quercetin, could generate a dose-response curve and have IC_{50} values less than 5 μmol/L.

Figure 2. Assay development and stability assessment. A. Unlabeled peptide 1 (Ac-PFKPP-NH2) and mutant peptide 2 (Ac-PAKPP-NH2) were titrated into a mixture of c-Cbl (RING) protein (3 μmol/L)+100 nmol/L probe 1 separately in the detergent-free system. IC_{50} (peptide 1) = 1.05 ± 0.09 μmol/L. B. Unlabeled peptide 1 and mutant peptide 2 were titrated into a mixture of c-Cbl (RING) protein (3 μmol/L)+100 nmol/L probe 1 separately in the detergent-present system. IC_{50} (peptide 1) = 1.06 ± 0.09 μmol/L. C and D, temperature dependence of K_d and ΔmP values in detergent-free or detergent-present system. c-Cbl (RING) protein was titrated against 100 nmol/L probe 1. E, Assessment of stability of binding experiments over time in detergent-free or detergent-present system. c-Cbl (RING) protein was titrated against 100 nmol/L probe 1. FP values were measured at 25 °C up to 180 min. F. Stability of binding experiments with increasing DMSO concentrations in detergent-free or detergent-present system. DMSO was titrated into constant amounts of c-Cbl (RING) protein (3 μmol/L) and probe 1 (100 nmol/L) mixture. The total reaction volume was maintained constant in all wells at 20 μL. The measurements were made at room temperature (25 °C) after 30 min of incubation.
were identified as hit compounds in the detergent-free system. There are only 12 compounds showed inhibitory activity at the concentration of 10 \( \mu \text{mol/L} \). Three candidates, methylprotopodioscin, leonuride, and Catalpol, were identified as hit compounds in the detergent-present system. All compounds have been tested in more extensive competitive binding assays. Two of the compounds from the detergent-free screen, tehmaglutin and quercetin, were verified as false positive hits possibly due to the aggregation (Table 4).

Discussion

Design and development of c-Cbl regulators is an active field of study because c-Cbl is associated with multiple diseases including obesity, diabetes and cancer [8,11–13]. There are reports of assays being developed to screen the c-Cbl TKB domain indicators [14,15]. Studies show that the majority of the binding energy of protein-protein interactions is contributed by a few amino acids at the interface [16]. Therefore, molecules derived from natural or bioactive peptides produced by plants, animals or humans are good candidates for screening. The potency of these peptides can be increased by enhancing hydrophobic, electrostatic and hydrogen-bonding interactions between the peptide and protein target. Crystallization studies show that c-Cbl binds to UbcH7 with its RING domain and its linker helix [17]. The RING domain provides a shallow groove which interacts with the L1 and L2 loops of UbcH7. This c-Cbl groove provides contacts for UbcH7 which include Phe-63 of the UbcH7 L1 loop as well as Pro-97 and Ala-98 of the UbcH7 L2 loop [17]. The Phe-63 (blue) makes multiple van der Waals contacts with Ile-383 on the c-Cbl RING domain. It also makes contacts with Trp-408, Cys-404, Ser-407, and Ser-411 from the 3 helix of the c-Cbl RING domain (Fig. 1A). The Pro-97 colored in blue of UbcH7 L2 loop makes

Table 2. Screen assay protocol.

| Step | Parameter           | Value         | Description                                      |
|------|---------------------|---------------|--------------------------------------------------|
| 1    | Plate master mixture| 19 \( \mu \text{l} \) | Master mixture of c-Cbl (RING) protein and probe 1 |
| 2    | Controls            | 1 \( \mu \text{l} \) | 10 \( \mu \text{mol/L} \) to 78 nmol/L titration series of peptide 1 |
| 3    | Library compounds   | 1 \( \mu \text{l} \) | 10 \( \mu \text{mol/L} \) to 78 nmol/L titration series |
| 4    | Incubate time       | 30 min        | Room temperature                                |
| 5    | Assay readout       | Ex/Em = 485/538 nm | ZS-2 plate reader                               |

Plates lidded until read.
doi:10.1371/journal.pone.0078042.t002

Table 3. FP assay performance and post-screen analysis summary.

| Category            | Parameters               | Descriptions                                                   |
|---------------------|--------------------------|---------------------------------------------------------------|
| Assay               | Nature of the assay      | Cell-free multicomponent competitive assay                    |
|                     | assay strategy           | Detection of c-Cbl (RING) domain regulator using fluorescence polarization assay |
| Reagents and sources| Source                   | Pharmacinc, China                                             |
|                      | Quality control          | All compounds assured by the lab as >98% pure on HPLC with QC data |
|                     | Concentration tested     | 5% DMSO for the initial screen; 8 concentration tested from 10 \( \mu \text{mol/L} \) to 78.125 nmol/L (half dilutions) |
|                      | Format                   | 384-well plate                                                |
|                     | Plate controls           | Positive control: peptide 1; negative control: 5% DMSO        |
|                      | Plate number and duration| 430 plates over 60 days                                       |
| Screen process      | Output, detector, analysis software | ZS-2 detector; Fixed endpoint; FP value, SigmaPlot             |
|                     | Normalization            | % inhibition = 100 \( \times \) (sample result – average of negative control)/(average of negative control – average of positive control) |
|                     | Performance              | \( Z' = 0.62 \) (detergent-free system) \( Z' = 0.73 \) (detergent-present system) |
|                     | Selection of actives     | Actives were selected from the primary screen using a threshold of better than 5 \( \mu \text{mol/L} \) (IC50) |
| Post-screen analysis| Retesting of initial actives | Original samples retested using screening assay condition; compounds with triplicated activity tested in dose-response mode (8 half dilutions) |
|                     | List of validated compounds| Table 4                                                         |

doi:10.1371/journal.pone.0078042.t003
contact with Ile-383, Trp-408, and Pro-417 of c-Cbl. The carbonyl group of Ala-98 of UbcH7 L2 loop makes a hydrogen bond with amide group on Pro-417 of c-Cbl which is another potential binding interface for chemical regulators (Fig. 1B). Based on these studies, fluorescein isothiocyanate (FITC) was used to label peptides derived from UbcH7 L1 loop or L2 loop structure which mimics the binding sequence (Table 1).

FP is a solution-based, homogeneous technique requiring no immobilization or separation of reaction components and therefore is suitable for HTS assays. The principle of the screen is to identify the compounds that displace probe 1 from the c-Cbl (RING) protein by detecting the resulting decrease in FP. The fluorescent labeled peptide (probe 1) bound to c-Cbl (RING) domain with a sub-micromolar dissociation constant was inhibited by peptide 1 (Fig. 2A & 2B). Therefore, probe 1 can be used as the fluorescent labeled probe for the FP assay.

It is widely accepted that aggregation, autofluorescence, and reactivity of artifacts in a HTS for inhibitors are potential causes for false positives [18–20]. It is also recognized that a substantial fraction of small molecules or natural compounds exhibit aggregating behavior leading to false positive results in screening assays [18]. This nonspecific attachment to target protein could be dramatically reduced by adding small amount of detergent to the assay buffer [19]. Therefore, we compared two screen conditions: detergent-free and detergent-present (0.01% Triton X-100) to assay buffer [19]. Therefore, we compared two screen conditions: detergent-free and detergent-present system.

In all, we report on the development of a fluorescence polarization based high-throughput assay to identify potential c-Cbl (RING) domain regulators. Based on the pilot screens and validation assays, we have confirmed the binding activities of the three hit compounds. Our data have proven this screen can be used as a fast, robust, and quantitative measure of binding affinity for a wide range of c-Cbl (RING) domain regulators. The quantitative nature of the data significantly aids the efforts to choose the hit compounds. The Z' factor of 0.73 indicates this assay could be easily adapted for HTS. We predict that this assay will be suitable for identifying small molecule regulators of the c-Cbl (RING) domain.

**Supporting Information**

**Figure S1** Schematic representation of domain structures of Cbl proteins. Numbers indicate amino acid position. (TIF)

**Figure S2** Schematic representation of c-Cbl WT and c-Cbl (RING) constructs used in this study. Numbers indicate amino acid position. (TIF)

**Acknowledgments**

We would like to thank Chengdu Medical College protein core facility for preparing the proteins.

**Author Contributions**

Conceived and designed the experiments: YS XX LS ZYP. Performed the experiments: XX LS YZ ZZ LZ MW QS XG WZ YS. Analyzed the data: XX LS YS. Contributed reagents/materials/analysis tools: XX LS YZ ZZ LZ MW QS XG WZ YS. Wrote the paper: ZYP.

**References**

1. Thien CB, Langdon WY (2001) Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2: 294–307.

2. Schmidt MH, Dikic I (2005) The Cbl interactome and its functions. Nat Rev Mol Cell Biol 6: 907–918.

---

**Table 4. Summary of hit compounds.**

| Number | Compound                | Derived from          | IC50 (μmol/L) | Primary screen | Validated |
|--------|-------------------------|-----------------------|---------------|---------------|----------|
|        |                         |                       |               | DF | DP | DF | DP |
| 1      | Methylprotodioscin      | Cochinchinese Asparagus Root | 4.8 | 4.0 | 4.2±0.5 | 4.0±0.8 |
| 2      | Leonuride               | Rehmannia glutinosa   | 3.5 | 3.8 | 4.6±0.8 | 4.5±1.1 |
| 3      | Catalpol                | Rehmannia glutinosa   | 2.9 | 2.3 | 2.7±0.6 | 3.2±0.9 |
| 4      | Tehmaglutin             | Rehmannia glutinosa   | 5.0 | >10 | 4.7±0.4 | NR |
| 5      | Quercetin               | Cuscuta chinensis Lam | 4.2 | >10 | 4.0±0.6 | NR |

DF: detergent-free system. DP: detergent-present system. NR: no dose response.

DOI:10.1371/journal.pone.0078042.t004
3. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK, Morse HC 3rd (1989) v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci U S A 86: 1168–1172.

4. Blake TJ, Shapiro M, Morse HC, (1991) The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif. Oncogene 6: 653–657.

5. Swaminathan G, Tyagankov AY (2006) The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 209: 21–43.

6. Sanjay A, Horne WC, Baron R (2001) The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinases. Sci STKE 2001: pe40.

7. Huang F, Gu H (2008) Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunol Rev 224: 229–238.

8. Miyake S, Lusher ML Jr., Andonissi CE, Lill NL, Ota S, et al. (1997) The Cbl protoonogene product: from an enigmatic oncogene to center stage of signal transduction. Crit Rev Oncog 8: 189–218.

9. Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, et al. (1999) Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 274: 31707–31712.

10. Sun Y, Zhang Z, Zhong L, Wu M, Su Q, et al. (2013) Identification of adiponectin receptor agonist utilizing a fluorescence polarization based high throughput assay. PLoS One 8: e63354.

11. Kumar EA, Yuan Z, Palermo NY, Dong L, Ahmad G, et al. (2012) Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain. J Med Chem 55: 3503–3507.

12. Mohapatra B, Ahmad G, Nadeau S, Zutshi N, An W, et al. (2013) Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta 1833: 122–139.

13. Naramura M, Nadeau S, Mohapatra B, Ahmad G, Mukhopadhyay C, et al. (2011) Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget 2: 245–250.

14. Kumar EA, Charvet CD, Lokesh GL, Natarajan A (2011) High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Anal Biochem 411: 254–260.

15. Kumar EA, Chen Q, Kizhake S, Kolar C, Kang M, et al. (2013) The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides. Sci Rep 3: 1639.

16. DeLano WL (2002) Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 12: 14–20.

17. Zheng N, Wang P, Jeffrey PD, Paulieich NP (2000) Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102: 533–539.

18. Chen LL, Liadzene EA, Finch KE, Heeres JT, Hergerrother PJ, et al. (2009) A method for identifying small molecule aggregators using photonic crystal bio sensor microplates. Conf Proc IEEE Eng Med Biol Soc 2009: 788–791.

19. Pohjala L, Tammmela P (2012) Aggregating behavior of phenolic compounds—a source of false bioassay results? Molecules 17: 10774–10780.

20. Jadhav A, Ferreira RS, Kusnapp C, Mott R, Austin CP, et al. (2010) Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem 53: 37–51.

21. Wang G, Chen H, Huang M, Wang N, Zhang J, et al. (2006) Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Cancer Lett 241: 102–109.

22. Deng YX, Zhang JX, Shi QZ, Chen YS, Qiu XM, et al. (2012) Anti-hyperglycemic effects and mechanism of traditional Chinese medicine Huanglian Wan in streptozocin-induced diabetic rats. J Ethnopharmacol 144: 425–432.

23. Dong Z, Chen CX (2013) Effect of catalpol on diabetic nephropathy in rats. Phytomedicine.

24. Huang WJ, Niu HS, Lin MH, Cheng JT, Hsu FL (2010) Anti-hyperglycemic effect of catalpol in streptozotocin-induced diabetic rats. J Nat Prod 73: 1170–1172.

25. Mahmoud MF, Hassan NA, El Bassossy HM, Fahmy A (2013) Quercetin Protects against Diabetes-Induced Exaggerated Vasoconstriction in Rats: Effect on Low Grade Inflammation. PLoS One 8: e63784.